Add like
Add dislike
Add to saved papers

Interleukin 20 Gene Polymorphism (rs1518108) is not Associated with Sustained Virological Response in Iranian Patients with Hepatitis C Virus Infection.

Clinical Laboratory 2017 September 2
METHODS: This case-control study, was performed on 136 blood samples based on 81 patients with chronic HCV genotypes 1 and 3 including 64 SVR positive and 17 negative and 55 healthy individual controls. DNA was isolated from the samples and the frequency of the polymorphism was analyzed using a PCR-RFLP method. Finally, the products were detected on 3.5% agarose gel electrophoresis.

RESULTS: The analysis of the data for C/T polymorphism indicated that the CC genotype was found in 19 of 64 patients who achieved SVR, while the TT genotype was detected in 3 patients and SVR was achieved in 2. Finally, heterozygous CT was identified in 53 patients and 10 patients were resistant to treatment.

CONCLUSIONS: The results did not support any significant effects of TT or CT genotypes on susceptibility to HCV infection (p = 0.935, OR = 1.031, CI = 0.464 - 2.026). Moreover, there was no significant correlation between SVR to PEG-IFN combined by ribavirin therapy in patients with genotype CC (p = 0.601, OR = 0.736, CI = 0.234 - 2.319).

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app